IRIDEX Corporation (IRIX)
Nasdaq · Healthcare · Medical Devices
$0.69+7.28%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $12.1M
- 52-week range
- $0.61 – $1.65
- 52-week change
- −42.34%
- EPS (trailing)
- −$0.21
- Next earnings
- Nov 17, 2026
Fiscal year to Jan 2026
- Revenue
- $52.7M (+8.23%)
- Net income
- −$4.4M
- Operating margin
- −4.9%
- Diluted EPS
- −$0.26
- Free cash flow
- −$2.3M
From the company’s annual report on SEC EDGAR.
About IRIDEX Corporation
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders.
Headquarters: Mountain View, United States · 93 employees · iridex.com